323 related articles for article (PubMed ID: 27580355)
1. CMV-specific immune reconstitution following allogeneic stem cell transplantation.
Blyth E; Withers B; Clancy L; Gottlieb D
Virulence; 2016 Nov; 7(8):967-980. PubMed ID: 27580355
[TBL] [Abstract][Full Text] [Related]
2. Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation.
Borchers S; Luther S; Lips U; Hahn N; Kontsendorn J; Stadler M; Buchholz S; Diedrich H; Eder M; Koehl U; Ganser A; Mischak-Weissinger E
Transpl Infect Dis; 2011 Jun; 13(3):222-36. PubMed ID: 21585633
[TBL] [Abstract][Full Text] [Related]
3. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients.
Abate D; Cesaro S; Cofano S; Fiscon M; Saldan A; Varotto S; Mengoli C; Pillon M; Calore E; Biasolo MA; Cusinato R; Barzon L; Messina C; Carli M; Palù G
Transplantation; 2012 Mar; 93(5):536-42. PubMed ID: 22314338
[TBL] [Abstract][Full Text] [Related]
5. Timing of CMV-specific effector memory T cells predicts viral replication and survival after allogeneic hematopoietic stem cell transplantation.
Espigado I; de la Cruz-Vicente F; BenMarzouk-Hidalgo OJ; Gracia-Ahufinger I; Garcia-Lozano JR; Aguilar-Guisado M; Cisneros JM; Urbano-Ispizua A; Perez-Romero P
Transpl Int; 2014 Dec; 27(12):1253-62. PubMed ID: 25070273
[TBL] [Abstract][Full Text] [Related]
6. Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV® assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications.
Tey SK; Kennedy GA; Cromer D; Davenport MP; Walker S; Jones LI; Crough T; Durrant ST; Morton JA; Butler JP; Misra AK; Hill GR; Khanna R
PLoS One; 2013; 8(10):e74744. PubMed ID: 24146744
[TBL] [Abstract][Full Text] [Related]
7. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.
Neuenhahn M; Albrecht J; Odendahl M; Schlott F; Dössinger G; Schiemann M; Lakshmipathi S; Martin K; Bunjes D; Harsdorf S; Weissinger EM; Menzel H; Verbeek M; Uharek L; Kröger N; Wagner E; Kobbe G; Schroeder T; Schmitt M; Held G; Herr W; Germeroth L; Bonig H; Tonn T; Einsele H; Busch DH; Grigoleit GU
Leukemia; 2017 Oct; 31(10):2161-2171. PubMed ID: 28090089
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation.
Peggs KS; Verfuerth S; Pizzey A; Chow SL; Thomson K; Mackinnon S
Clin Infect Dis; 2009 Dec; 49(12):1851-60. PubMed ID: 19911966
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital.
Fleming T; Dunne J; Crowley B
J Med Virol; 2010 Mar; 82(3):433-40. PubMed ID: 20087937
[TBL] [Abstract][Full Text] [Related]
11. Persistent CMV infection after allogeneic hematopoietic stem cell transplantation in a CMV-seronegative donor-to-positive recipient constellation: Development of multidrug resistance in the absence of anti-viral cellular immunity.
Herling M; Schröder L; Awerkiew S; Chakupurakal G; Holtick U; Kaiser R; Pfister H; Scheid C; Di Cristanziano V
J Clin Virol; 2016 Jan; 74():57-60. PubMed ID: 26672492
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus in hematopoietic stem cell transplant recipients - management of infection.
Locatelli F; Bertaina A; Bertaina V; Merli P
Expert Rev Hematol; 2016 Nov; 9(11):1093-1105. PubMed ID: 27690683
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus-Specific CD8+ T-Cells With Different T-Cell Receptor Affinities Segregate T-Cell Phenotypes and Correlate With Chronic Graft-Versus-Host Disease in Patients Post-Hematopoietic Stem Cell Transplantation.
Poiret T; Axelsson-Robertson R; Remberger M; Luo XH; Rao M; Nagchowdhury A; Von Landenberg A; Ernberg I; Ringden O; Maeurer M
Front Immunol; 2018; 9():760. PubMed ID: 29692783
[TBL] [Abstract][Full Text] [Related]
14. Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease.
Bhutani D; Dyson G; Manasa R; Deol A; Ratanatharathorn V; Ayash L; Abidi M; Lum LG; Al-Kadhimi Z; Uberti JP
Biol Blood Marrow Transplant; 2015 Jan; 21(1):159-64. PubMed ID: 25445637
[TBL] [Abstract][Full Text] [Related]
15. Coinfection with Human Cytomegalovirus Genetic Variants in Transplant Recipients and Its Impact on Antiviral T Cell Immune Reconstitution.
Smith C; Brennan RM; Tey SK; Smyth MJ; Burrows SR; Miles JJ; Hill GR; Khanna R
J Virol; 2016 Aug; 90(16):7497-507. PubMed ID: 27279616
[TBL] [Abstract][Full Text] [Related]
16. Response to antiviral therapy in haematopoietic stem cell transplant recipients with cytomegalovirus (CMV) reactivation according to the donor CMV serological status.
Servais S; Dumontier N; Biard L; Schnepf N; Resche-Rigon M; Peffault de Latour R; Scieux C; Robin M; Meunier M; Xhaard A; Sicre de Fontbrune F; Le Goff J; Socié G; Simon F; Mazeron MC
Clin Microbiol Infect; 2016 Mar; 22(3):289.e1-7. PubMed ID: 26627339
[TBL] [Abstract][Full Text] [Related]
17. The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients.
Ciáurriz M; Zabalza A; Beloki L; Mansilla C; Pérez-Valderrama E; Lachén M; Bandrés E; Olavarría E; Ramírez N
Cell Mol Life Sci; 2015 Nov; 72(21):4049-62. PubMed ID: 26174234
[TBL] [Abstract][Full Text] [Related]
18. Early CMV replication and subsequent chronic GVHD have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia.
Jang JE; Kim SJ; Cheong JW; Hyun SY; Kim YD; Kim YR; Kim JS; Min YH
Ann Hematol; 2015 Feb; 94(2):275-82. PubMed ID: 25135450
[TBL] [Abstract][Full Text] [Related]
19. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection.
Lilleri D; Fornara C; Chiesa A; Caldera D; Alessandrino EP; Gerna G
Haematologica; 2008 Feb; 93(2):248-56. PubMed ID: 18245650
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus Status and the Outcome of T Cell-Replete Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation.
Verduyn Lunel FM; Raymakers R; van Dijk A; van der Wagen L; Minnema MC; Kuball J
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1883-1887. PubMed ID: 27470287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
